Menu
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scienti c instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with its customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.
40 Manning Rd
Billerica, Massachusetts 01821-3915
Phone: 19786633660
www.bruker.com
No summary available.
Bruker Corporation (NASDAQ: BRKR) price move into positive territory Monday, on word it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis. Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoStrings business, including the nCounter, GeoMx, CosMx and AtoMx product lines, for approximately $392.6 million in cash, and the assumption of certain liabilities. In 2023, NanoString generated revenues of approximately $168 million. Last Friday, the transaction was approved under a court-supervised Chapter 11 sale process pursuant to Section 363 of the U.S. Bankruptcy Code, and it is expected to close in the second quarter of 2024, subject to customary closing conditions. NanoString is a provider of life science tools for discovery and translational research with leading solutions for spatial transcriptomics and gene expression analysis.
Bruker Corp (BRKR) just unveiled an update. Bruker Corporation has successfully bid $392.6 million to acquire the assets and certain liabilities of…
Bruker intends to acquire NanoString Technologies for $392.6M, expanding its spatial biology portfolio.
Bruker Corporation (Nasdaq: BRKR) today announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of solutions for spatial transcriptomics and gene expression analysis. Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString’s Jetzt den vollständigen Artikel lesen
Bruker (BRKR) has entered into a definitive acquisition agreement with NanoString Technologies, Inc., to acquire its business for approximately $392.6 million. The deal includes the acquisition of NanoString''s product lines, such as nCounter®, GeoMx®, CosMx™, and AtoMx™. NanoString, a leader in gene expression profiling and spatial transcriptomics, generated revenues of around $168 million in 2023. The acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions.
An update from NanoString Technologies (NSTGQ) is now available. NanoString Technologies, Inc. underwent a significant shift in its restructuring j…
No summary available.
https://www.investing.com/news/press-releases/bruker-introduces-novel-nmr-scientific-capabilities-for-structural-biology-discoveries-in-membrane-proteins-and-protein-aggregates-93CH-3369186
https://www.investing.com/news/press-releases/bruker-advances-magnet-technology-for-broader-adoption-of-nmr-in-academic-and-biopharma-research-and-process-analytical-technologies-93CH-3369184